Thu Ha Pham, Sylvain Lecomte, Remy Le Guevel, Aurélie Lardenois, Bertrand Evrard, Frédéric Chalmel, François Ferriere, Patrick Balaguer, Theo Efstathiou, Farzad Pakdel
Recent studies strongly support the use of the aryl hydrocarbon receptor (AhR) as a therapeutic target in breast cancer. Glyceollins, a group of soybean phytoalexins, are known to exert therapeutic effects in chronic human diseases and also in cancer. To investigate the interaction between glyceollin I (GI), glyceollin II (GII) and AhR, a computational docking analysis, luciferase assays, immunofluorescence and transcriptome analyses were performed with different cancer cell lines. The docking experiments predicted that GI and GII can enter into the AhR binding pocket, but their interactions with the amino acids of the binding site differ, in part, from those interacting with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)...
February 18, 2020: International Journal of Molecular Sciences